Formulation Optimization and in Vitro-in Vivo Evaluation of Alpha Lipoic Acid-Loaded Lipid-Polymer Hybrid Nanoparticles Via Design of Experiments

被引:0
|
作者
Coban, Ozlem [1 ,2 ,6 ]
Demirtas, Hatice [1 ]
Kaya-Yasar, Yesim [3 ]
Engin, Seckin [3 ]
Yildirim, Sercan [4 ]
Morsali, Mohammed Reza [5 ]
机构
[1] Karadeniz Tech Univ, Fac Pharm, Dept Pharmaceut Technol, TR-61080 Trabzon, Turkiye
[2] Karadeniz Tech Univ, Drug & Pharmaceut Technol Applicat & Res Ctr, TR-61080 Trabzon, Turkiye
[3] Karadeniz Tech Univ, Fac Pharm, Dept Pharmacol, TR-61080 Trabzon, Turkiye
[4] Karadeniz Tech Univ, Fac Pharm, Dept Analyt Chem, TR-61080 Trabzon, Turkiye
[5] Karadeniz Tech Univ, Fac Pharm, TR-61080 Trabzon, Turkiye
[6] Turkish Med & Med Devices Agcy, Ankara, Turkiye
关键词
Design of experiments (DoE); Alpha lipoic acid (ALA); Lipid-polymer hybrid nanoparticles (LPHNPs); Plackett-burman; Box-behnken design (BBD); in vivo anti-inflammatory; DRUG-DELIVERY; PLGA NANOPARTICLES; PARTICLE-SIZE; LIPOSOMES; QUALITY; VARIABLES; THERAPY; PH;
D O I
10.1007/s12247-025-09931-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
PurposeAlpha lipoic acid (ALA) is a natural compound that has recently gained attention for its anti-inflammatory potential. ALA has a low bioavailability and in vitro stability, making its clinical use a challenge. Lipid-polymer hybrid nanoparticles (LPHNPs), a newly discovered core-shell nanostructures, are derived from liposomes and polymeric nanoparticles, and they were commonly used to improve in vivo efficiency and stability of active substances.MethodsThe current study aimed to prepare ALA-loaded LPHNPs via the design of experiments (DoE) approach to improve oral bioavailability and in vitro stability of ALA. The Plackett-Burman design was used to select independent variables by evaluating the effects of drug amount, stirring rate, polymer amount, lipid/polymer ratio, water/organic solvent (W/Os) ratio, and polyvinyl alcohol (PVA) concentration on formulation properties. Afterward, statistically significant formulation parameters were optimized using the Box-Behnken design (BBD). Finally, the in vitro properties were evaluated, and the in vivo anti-inflammatory effect of the optimized formulation was tested using formalin-induced paw edema in mice.ResultsThe main factors affecting the mean particle size (mPS), polydispersity index (PdI), and zeta potential (ZP) values of ALA-loaded LPHNPs were the stirring rate, W/Os ratio, and PVA concentration; however, the independent variables had no significant effect on encapsulation efficiency (EE). Furthermore, optimized ALA-loaded LPHNPs also significantly reduced paw edema thickness and volume with a prolonged duration of action compared to ALA solution during 6 h after formalin administration.ConclusionThe optimized ALA-loaded LPHNPs with core-shell structure had sustained control release up to day 17 and exhibited superior colloidal and chemical stability under various in vitro conditions and prolonged and robust in vivo anti-inflammatory effect.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Discovery and in Vivo Evaluation of Novel RGD-Modified Lipid-Polymer Hybrid Nanoparticles for Targeted Drug Delivery
    Zhao, Yinbo
    Lin, Dayong
    Wu, Fengbo
    Guo, Li
    He, Gu
    Ouyang, Liang
    Song, Xiangrong
    Huang, Wei
    Li, Xiang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (10): : 17565 - 17576
  • [42] Development, Optimization and In Vitro Evaluation of Etoposide loaded Lipid Polymer Hybrid Nanoparticles for Controlled Drug Delivery on Lung Cancer
    Kazemabadi, Fatemeh Zare
    Heydarinasab, Amir
    Akbarzadehkhiyavi, Azim
    Ardjmand, Mehdi
    CHEMICAL METHODOLOGIES, 2021, 5 (02): : 135 - 152
  • [43] Dexketoprofen Trometamol-Loaded Kollidon® SR and Eudragit® RS 100 Polymeric Nanoparticles: Formulation and In Vitro-In Vivo Evaluation
    Ozturk, A. Alper
    Yenilmez, Evrim
    Arslan, Rana
    Senel, Behiye
    Yazan, Yasemin
    LATIN AMERICAN JOURNAL OF PHARMACY, 2017, 36 (11): : 2153 - 2165
  • [44] Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
    Wu, Bo
    Lu, Shu-Ting
    Zhang, Liu-Jie
    Zhuo, Ren-Xi
    Xu, Hai-Bo
    Huang, Shi-Wen
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12 : 1853 - 1862
  • [45] Formulation Development, Optimization, and In Vitro-In Vivo Characterization of Natamycin-Loaded PEGylated Nano-Lipid Carriers for Ocular Applications
    Patil, Akash
    Lakhani, Prit
    Taskar, Pranjal
    Wu, Kai-Wei
    Sweeney, Corinne
    Avula, Bharathi
    Wang, Yan-Hong
    Khan, Ikhlas A.
    Majumdar, Soumyajit
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 107 (08) : 2160 - 2171
  • [46] Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation
    Kumar, Gaurav
    Sharma, Sadhna
    Shafiq, Nusrat
    Khuller, Gopal Krishan
    Malhotra, Samir
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (06) : 2165 - 2176
  • [47] Development of Novel Polymer-Lipid Hybrid Nanoparticles of Tamoxifen: In Vitro and In Vivo Evaluation
    Varthya, Mansingh
    Pawar, Harish
    Singh, Charan
    Dora, Chander Parkash
    Jena, Sunil Kumar
    Suresh, Sarasija
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2016, 16 (01) : 253 - 260
  • [48] Furosemide Loaded Silica-Lipid Hybrid Microparticles: Formulation Development, in vitro and ex vivo Evaluation
    Sambaraj, Swapna
    Ammula, Divya
    Nagabandi, Vijaykumar
    ADVANCED PHARMACEUTICAL BULLETIN, 2015, 5 (03) : 403 - 409
  • [49] Development and Optimization of Itraconazole-Loaded Solid Lipid Nanoparticles for Topical Administration Using High Shear Homogenization Process by Design of Experiments: In Vitro, Ex Vivo and In Vivo Evaluation
    Neeraj Kumar
    Shishu Goindi
    AAPS PharmSciTech, 22
  • [50] Development and Optimization of Itraconazole-Loaded Solid Lipid Nanoparticles for Topical Administration Using High Shear Homogenization Process by Design of Experiments: In Vitro, Ex Vivo and In Vivo Evaluation
    Kumar, Neeraj
    Goindi, Shishu
    AAPS PHARMSCITECH, 2021, 22 (07)